Wegovy Alternatives: Options For Weight Loss In The UK

Reasons people look for Wegovy alternatives

People look for Wegovy alternatives for several reasons: side effects, cost, supply, dislike of injections, a preference for tablets, or because their current weight loss medication is not producing enough benefit. Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces appetite and helps people lose weight when used alongside a reduced-calorie diet and physical activity. [1]

Some people are happy to continue Wegovy online, while others may benefit from discussing alternative medications with a prescriber. UK options include Mounjaro, liraglutide, orlistat, Mysimba and newer oral medicines. This guide is for adults comparing treatment before starting or considering a switch. It explains how the main injections and tablets differ in effectiveness, cost, safety and convenience.

When searching for “Wegovy alternatives UK”, look beyond headline weight loss figures. Medical history, body mass index, blood sugar levels, high blood pressure, heart disease, previous side effects and personal preferences can all affect suitability. [1, 2]

Why are people stopping Wegovy? Common reasons include gastrointestinal side effects, cost, availability, dislike of an injectable medication or limited response. UK product information states that treatment should be discontinued if an adult has not lost at least 5% of their initial body weight after 6 months on the 2.4 mg dose. [1] Discuss stopping or switching with your prescriber rather than choosing from a comparison chart alone.

Wegovy alternatives compared

There is no single replacement that suits everyone. Alternatives to Wegovy include incretin injections, tablets and medicines with different mechanisms. NICE includes tirzepatide, semaglutide, liraglutide and orlistat among options for managing overweight and obesity in adults, subject to individual criteria. [2]

Option	Active ingredient	Form	UK status	Practical difference
Mounjaro	Tirzepatide	Once-weekly injection	Licensed for managing overweight or obesity in eligible adults	Acts on GIP and GLP-1 receptors
Saxenda/liraglutide	Liraglutide	Daily injection	Licensed for managing overweight or obesity in eligible adults	Older incretin option requiring daily dosing
Ozempic	Semaglutide	Weekly injection	Licensed for type 2 diabetes, not obesity treatment	Contains semaglutide like Wegovy, but has a different licensed use
Orlistat/Xenical	Orlistat	Capsule	Licensed for managing overweight or obesity in eligible adults	Reduces absorption of dietary fat
Mysimba	Naltrexone/bupropion	Tablet	Licensed for managing overweight or obesity in eligible adults	Acts on appetite and reward pathways

These options can support adults trying to lose weight, but differ in mechanism, expected weight loss, side effects, dosing and eligibility. An effective weight loss injection on average is not automatically the best individual choice.

Mounjaro (tirzepatide)

Mounjaro (tirzepatide) is a prescription medication licensed in the UK to support weight loss and weight maintenance in eligible adults. Its active ingredient, tirzepatide, activates receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). This dual action can reduce appetite, help people eat fewer calories, control blood sugar levels and support significant weight loss. [3]

In SURMOUNT-1, the 15 mg dose produced an average 22.5% reduction in body weight at 72 weeks under the trial-product analysis, and 96.3% of participants at that dose lost at least 5%; the treatment-regimen figure was 20.9%. [3] More importantly for a direct comparison, the SURMOUNT-5 clinical trial published in the New England Journal of Medicine compared maximum tolerated tirzepatide 10 or 15 mg with semaglutide 1.7 or 2.4 mg. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. [4]

Mounjaro is therefore a highly effective weight loss injection with strong direct evidence against standard-dose Wegovy for helping people lose weight, but it is not better for every patient. Wegovy now also has a 7.2 mg dose for some adults with obesity. 

In STEP UP, it produced 18.7% average weight loss at 72 weeks under the treatment-policy analysis, versus 15.6% with 2.4 mg and 3.9% with placebo. [5] A trial-product analysis assuming continued assigned treatment estimated 20.7% with 7.2 mg. [5] This dose was not tested against tirzepatide in SURMOUNT-5. It is also worth noting who the 7.2 mg dose is for: it is authorised only for adults with obesity (a BMI of 30 or above), and not for people with a BMI between 27 and 30, nor for those taking Wegovy to reduce cardiovascular risk.

Liraglutide injections

Liraglutide is an older GLP-1 receptor agonist. Saxenda is a liraglutide brand licensed for managing overweight or obesity in eligible adults. Unlike Wegovy and Mounjaro, it is injected once daily rather than weekly. Its active ingredient mimics glucagon-like peptide-1, helping regulate appetite and calorie intake. [6]

In a 56-week clinical trial reported in the Saxenda product information, average weight loss was 8.0% with liraglutide versus 2.6% with placebo, and 63.5% of participants lost at least 5% of their body weight. [6] These figures are lower than the average reductions seen with newer incretin medicines in separate clinical trials, although cross-trial comparisons are imperfect.

Liraglutide may still be an effective weight loss injection when another medicine is unsuitable or poorly tolerated. It requires daily administration, and gastrointestinal effects such as nausea and stomach pain can occur.

Ozempic (semaglutide)

Ozempic and Wegovy contain the same active ingredient, semaglutide, but Ozempic's UK licence is for insufficiently controlled type 2 diabetes rather than obesity treatment. [7] Its maximum licensed dose is 2 mg once weekly for glycaemic control, so calling it a lower dose version of Wegovy misses an important regulatory difference.

Ozempic can reduce appetite, blood sugar and body weight, but using it specifically to treat obesity is off label in the UK. If Ozempic is prescribed off label for weight loss, the prescriber should explain why. Being prescribed off label does not give it a UK label for weight loss; Wegovy is approved for weight loss and weight management in eligible patients. [1, 7]

Our Wegovy vs Ozempic guide explains the difference. An off label prescription can be clinically appropriate, but Ozempic is not a generic version of Wegovy simply because both use the same active ingredient.

Lifestyle support alongside treatment

   

Medication can make it easier for some people to lose weight, but weight loss treatments are designed to sit alongside sustainable lifestyle support rather than replace it. NICE recommends these medicines alongside dietary and physical-activity measures appropriate to the treatment and the person. [2]

The practical goal is often a sustainable energy deficit, taking in fewer calories than the body uses, without extreme restriction. A reduced calorie diet built around protein, fibre-rich foods, fruit, vegetables and suitable portions can support a healthy weight while helping preserve muscle during weight loss.

Regular activity can improve health outcomes beyond the number on the scales, which is why weight management is broader than medication alone. Potential health benefits of clinically meaningful weight loss include improvements in blood pressure, blood sugar levels, mobility and risk factors linked to heart disease. [2] Maintaining these habits matters because weight gain can occur after a weight loss medication is stopped, even after successful treatment. [1]

For severe obesity, weight loss surgery may be another evidence-based pathway. The right route depends on individual circumstances and NHS or private eligibility. Our overview of weight loss treatments explains the broader options.

Choosing the most suitable Wegovy alternatives

Choosing between alternatives to Wegovy means balancing effectiveness, safety, cost, administration and what is realistic to continue. A systematic review and network meta-analysis in Nature Medicine, covering 56 randomised clinical trials and more than 60,000 participants, found greater weight loss than placebo with orlistat, liraglutide, naltrexone/bupropion, semaglutide and tirzepatide. 

In this medical research, average reductions above 10% were seen only with semaglutide and tirzepatide. [8]

Those averages do not create a universal ranking. Suitability also depends on health condition, other medicines, previous response, side effects and ability to follow the dosing schedule.

Best weight loss medication

If “best” means the greatest average weight loss in a direct head-to-head trial, Mounjaro currently has the strongest evidence against standard-dose Wegovy. SURMOUNT-5 showed 20.2% average weight loss with tirzepatide versus 13.7% with semaglutide 1.7 or 2.4 mg at 72 weeks. [4]

This does not make Mounjaro the best weight loss medication for everyone: the study did not compare tirzepatide with Wegovy 7.2 mg, and response, side effects, contraindications and adherence still matter. People lose weight at different rates even within clinical trials. In STEP 1, 83.5% taking semaglutide 2.4 mg achieved at least 5% weight loss at 68 weeks. [1]

Mounjaro's dual-incretin action may also be relevant where blood sugar control is part of the clinical picture. [3] Wegovy 2.4 mg is also licensed in the UK to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and a BMI of at least 27 kg/m², and NICE recommends it for this use. [1, 9] Mounjaro does not currently have an equivalent UK cardiovascular risk-reduction indication. [3] This distinction may be important when choosing between treatments for someone with established cardiovascular disease.

Best for cost

There is no single cheapest option because prices vary by provider, strength and what the service includes. At Apomeds, checked on 24 August 2026, Wegovy injections currently start from £97.93 for four weeks, while Mounjaro starts from £142.99. These prices include the medication, delivery and the Apo Global platform fee, but exclude a doctor's fee where applicable.

Dose matters. Higher strengths cost more, so compare the same treatment period and check whether clinical support, prescribing and delivery are included when looking for cheaper alternatives to Wegovy. Orlistat is also available in a lower dose from pharmacies without a prescription under some brands. NHS guidance says it reduces dietary-fat absorption, so about one-third of fat eaten passes through the bowel. [10]

What is the “poor man's alternative to Ozempic”? There is no medically recognised product by that name. Orlistat may be a lower-cost weight loss medication that can help eligible adults lose weight, but it works differently and is not a generic version of semaglutide. Price should be weighed against benefit, side effects and suitability.

Is Zepbound cheaper than Wegovy? Zepbound is a US tirzepatide brand and, like Mounjaro, acts as a dual GIP and GLP-1 agonist. [11] Its US list price does not represent UK private treatment costs, so dollar-price comparisons are not useful for UK weight loss treatments.

Best for tablets or non-injectable options

Several non-injectable choices exist for people who want to lose weight without an injection. Orlistat acts in the digestive system rather than on incretin pathways, and NICE allows it to be prescribed in primary care and other settings. [2] Prescription Xenical contains 120 mg orlistat and is taken with main meals; treatment should stop after 12 weeks if at least 5% of starting body weight has not been lost. [12] In pooled studies, 37% taking orlistat versus 19% taking placebo had lost at least 5% at 12 weeks. [12]

Mysimba is another weight loss pill. It combines naltrexone with bupropion hydrochloride and targets brain pathways involved in appetite and food reward. The dose rises over four weeks to two tablets twice daily; treatment should stop after 16 weeks if at least 5% of initial body weight has not been lost. [13] 

In NB-301, 31% of the randomised Mysimba group achieved at least 5% weight loss versus 12% with placebo; among trial completers, the figures were 62% and 23%. [13] The often-quoted 62% therefore applies to completers, not everyone randomised. 

Oral Wegovy is another weight loss pill and contains semaglutide. In OASIS 4, published in the New England Journal of Medicine, the 25 mg daily tablet produced 13.6% average weight loss at week 64 versus 2.2% with placebo. [14]

A newer oral option is Foundayo (orforglipron). The MHRA authorised it on 10 August 2026 for weight loss and weight maintenance in eligible adults, so it is approved for weight loss in the UK, making the UK the first country in Europe to approve this once-daily tablet for weight management and type 2 diabetes. [15] Foundayo can be taken at any time of day, with or without food or water. [16]

ATTAIN-1, reported in the New England Journal of Medicine, tested hard-capsule orforglipron for 72 weeks. Using the treatment-regimen estimand, the highest trial dose produced 11.2% average weight loss versus 2.1% with placebo. [17] Marketed Foundayo film-coated tablets use different strengths and are not substitutable mg-for-mg with the trial capsules. [16]

Some tablet alternatives frequently mentioned online are US rather than UK options. Qsymia combines phentermine and topiramate and is a US oral obesity medicine; it does not appear among NICE's current medicine options for adult weight management in England. [2, 18] Contrave is the US naltrexone/bupropion product and is taken twice daily after dose escalation; the relevant UK product with these active ingredients is Mysimba. [13, 19]

Safety, side effects and who these medicines may not suit

   

Safety profiles vary between weight loss treatments, so switching because one medicine causes side effects does not guarantee another will be symptom-free. GLP-1 agonists and dual GIP/GLP-1 medicines commonly cause gastrointestinal effects such as nausea, vomiting, diarrhoea, constipation, stomach pain and abdominal pain. They can also affect blood sugar levels; low blood sugar is particularly relevant when certain diabetes drugs are used alongside medicines that lower glucose. [1, 3]

Non-GLP-1 options bring different trade-offs. Orlistat can cause oily stools and urgency because unabsorbed fat passes through the bowel. [10] Mysimba can raise blood pressure and is contraindicated with uncontrolled hypertension and seizure disorders, among other situations. [13]

Pregnancy, breastfeeding, pancreatitis risk, gallbladder disease, severe gastrointestinal disease, other prescription medication and existing heart disease can affect suitability. [1, 3, 6, 13] One difference between the two main injections matters here: tirzepatide can reduce the effectiveness of the contraceptive pill, so a non-oral method or an added barrier method is advised for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase, whereas semaglutide has not been found to have this effect. 

A clinician may use a lower dose or slower escalation for tolerability, but do not change a prescribed dose yourself. Anyone planning a pregnancy should also factor in the timing: semaglutide stays in the body longer and is usually stopped about two months beforehand, against about one month for tirzepatide.

Persistent severe abdominal pain can be a sign of acute pancreatitis and needs immediate medical assessment. [1] Serious allergic reactions can occur with semaglutide and tirzepatide; symptoms such as difficulty breathing or swelling of the face or throat require urgent medical help. [1, 3, 20] Because these medicines slow gastric emptying, the stomach may also still contain food after the usual pre-operative fasting, and stomach contents being inhaled into the lungs during general anaesthesia or deep sedation has been reported. Tell the surgical team and anaesthetist about the treatment before any planned procedure.

Weight loss medicines should not be combined or switched without professional advice. The MHRA warns that GLP-1 medicines are prescription-only and should not be bought from unregulated sellers. Products supplied as powder in vials that must be mixed before injection are not authorised UK GLP-1 medicines. [21] 

In the US, the FDA separately warns that unapproved compounded semaglutide and tirzepatide do not undergo FDA review for safety, effectiveness or quality before marketing. [22] These products should not be treated as legitimate alternatives to Wegovy in a UK comparison.

Frequently asked questions

The best choice depends on effectiveness, cost, formulation, side effects and medical history. These answers cover common questions about alternatives to Wegovy.

What is the best alternative to Wegovy?

Mounjaro has the strongest direct comparative evidence against standard-dose Wegovy if average weight loss is the main priority: tirzepatide produced greater weight reduction than semaglutide 1.7 or 2.4 mg in SURMOUNT-5. [4] There is still no universally best option; liraglutide, orlistat, Mysimba and licensed oral GLP-1 agonists may suit different people depending on eligibility, side effects, cost and preference.

Is there a cheaper alternative to Wegovy?

Cheaper alternatives to Wegovy may be available, but the lowest price does not make a treatment more suitable. Orlistat, for example, is a non-injectable option and a lower-dose version can be supplied by pharmacies without a prescription. [10]

When comparing price, look at the full treatment period, dose and included clinical support. Zepbound prices quoted in dollars are US figures and should not be used to judge UK costs; the UK tirzepatide brand discussed here is Mounjaro. [11]

Are there natural alternatives to Wegovy?

No food, supplement or lifestyle measure is a direct pharmacological equivalent of semaglutide. [1] Here, “natural alternatives” usually refers to dietary changes, physical activity, sleep and behavioural support rather than a medicine with the same effect.

These measures remain important whether or not medication is used. Sustainably eating fewer calories, increasing activity and building habits that support a healthy weight can improve long-term weight control, but they should not be presented as a direct substitute for a GLP-1 medicine.

Is Mounjaro better than Wegovy for weight loss?

In the Mounjaro vs Wegovy SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide 1.7 or 2.4 mg: 20.2% versus 13.7% at 72 weeks. [4] This does not prove Mounjaro is better for everyone, and the trial did not compare tirzepatide with Wegovy 7.2 mg. Safety, medical history, blood sugar, cost, and response still determine which weight loss medication may be suitable.

Can weight loss injections be combined?

No. GLP-1 or dual-incretin weight loss injections should not be combined. Wegovy product information states that semaglutide should not be used with other GLP-1 receptor agonist medicines. [1]

If you are switching from one treatment to another, your prescriber should tell you when to stop one medicine and start the next. Do not overlap injections or create your own switching schedule.